Application value of coagulation indices and neutrophil-to-lymphocyte ratio for assessing coagulation status of ovarian cancer patients / 肿瘤研究与临床

ABSTRACT

Objective:To explore the clinical application value of general coagulation indices and neutrophil-to-lymphocyte ratio (NLR) for assessing coagulation status of patients with ovarian cancer.Methods:The data of 190 patients with ovarian cancer who were admitted to the Second Hospital of Shanxi Medical University from October 2019 to September 2022 were retrospectively analyzed. According to the International Federation of Gynecology and Obstetrics (FIGO) staging, the patients were divided into early (stage Ⅰ-Ⅱ) ovarian cancer group (70 cases) and advanced (stage Ⅲ-Ⅳ) ovarian cancer group (120 cases). Forty-four patients with benign ovarian tumors who were treated in the Second Hospital of Shanxi Medical University during the same period were selected. Plasma D-dimer (D-D), activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen (FIB) and thrombin time (TT) were tested. Platelet count (Plt), neutrophil count and lymphocyte count were measured by blood cell analyzer, and NLR was calculated. The receiver operating characteristic (ROC) curve was used to analyze the value of coagulation indices and NLR in the assessment of venous thromboembolism (VTE) in patients with ovarian cancer.Results:Compared with the benign ovarian tumor group, PT of patients in the early and advanced ovarian cancer groups was shorter (both P < 0.05), and D-D and Plt increased (both P < 0.05). Compared with the benign ovarian tumors group, TT of patients in the advanced ovarian cancer group decreased ( P < 0.05), and FIB and NLR increased (both P < 0.05). Compared with the early ovarian cancer group, PT and TT in the advanced ovarian cancer group were shorter (both P < 0.05), and FIB, D-D, NLR and Plt increased (all P < 0.05). The optimal cut-off values of FIB, D-D and NLR in stage Ⅰ-Ⅱ and stage Ⅲ-Ⅳ patients with VTE in ovarian cancer group were 3.165, 333.500 and 2.455, and the area under the curve (AUC) was 0.731, 0.837 and 0.759. Conclusions:The coagulation indices of patients with ovarian cancer are abnormal during treatment, suggesting that patients may produce active thrombosis, and the symptoms of patients in advanced stage are more serious.